CTOs on the Move

Annexon Biosciences

www.annexonbio.com

 
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.annexonbio.com
  • 180 Kimball Way 2nd Floor, Suite 200
    South San Francisco, CA USA 94080
  • Phone: 650.822.5500

Executives

Name Title Contact Details
David Green
VP, Head of IT Profile
Ted Yednock
Executive Vice President and Chief Innovation Officer Profile

Funding

Annexon Biosciences raised $44M on 06/24/2016
Annexon Biosciences raised $75M on 12/19/2018

Similar Companies

Cathay Industrial Biotech

Cathay Industrial Biotech is a Mt Zion, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fujifilm Diosynth Biotechnologies

As a CDMO our focus is to combine technical leadership in cell culture, microbial fermentation and viral vectors with world class cGMP manufacturing facilities to advance tomorrow`s medicines. For over 25 years our focus has been on supporting our customers with the development and manufacture of recombinant proteins, viral vaccines and gene therapies.

Biohaven Pharmaceutical

Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.

Apogee Therapeutics

Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.

LC Sciences

LC Sciences is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.